Lynch Regenerative Medicine has completed participant enrolment in a Phase II trial assessing the rhPDGF-BB as an adjunctive therapy for surgical wounds following skin cancer excision.

The post Enrolment concludes in Lynch’s Phase II rhPDGF-BB study appeared first on Clinical Trials Arena.